Johnson & Johnson announced the submission of regulatory applications to the U.S. FDA and European Medicines Agency seeking approval of a ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...

In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

Praxis recognized $0.3 million in collaboration revenue during the three months ended September 30, 2024, compared to $0.5 million during the three months ended September 30, 2023. The decrease of ...

Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

In July 2021, the European Medicines Agency’s safety committee ruled that Zynteglo’s benefits outweigh its risks and the hold on its sales has been lifted. However, by early 2022 Zynteglo was ...

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...